Gradiant Bioconvergence has established over 800 patient-derived organoids from patients with genetic profiles from NGS, including WES and RNA-seq. The PDOs are also paired with normal organoids and matched with patient information and drug responsiveness data. The PDO models are available for drug screening and biomarker discovery services. Based on genomic and drug responsiveness data, we are identifying new oncology targets through our AI-driven target discovery and CRISPR-based PDO platform.
Products